×
For best experience we recommend to activate Javascript in your browser.
Recombinant MSTN (Trevogrumab Biosimilar) antibody
The Human Monoclonal anti-MSTN (Trevogrumab Biosimilar) antibody is suitable to detect MSTN (Trevogrumab Biosimilar) in samples from Human.
Catalog No. ABIN7598065
$401.14
Plus shipping costs $50.00, if applicable $20.00 dry ice
1 mg ABIN7598416
100 μg ABIN7598065
1 mg ABIN7598416
100 μg ABIN7598065
Delivery in 12 to 15 Business Days
Quick Overview for Recombinant MSTN (Trevogrumab Biosimilar) antibody (ABIN7598065)
Target
MSTN (Trevogrumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
All hosts for MSTN (Trevogrumab Biosimilar) antibodies
Human
Clonality
All clonalities for MSTN (Trevogrumab Biosimilar) antibodies
Monoclonal
Conjugate
All conjugates for MSTN (Trevogrumab Biosimilar) antibodies
This MSTN (Trevogrumab Biosimilar) antibody is un-conjugated
Grade
Research Grade
Product Details anti-MSTN (Trevogrumab Biosimilar) Antibody
(hide)
Expression System
Mammalian cells
Purpose
Research Grade Trevogrumab Biosimilar Antibody
Specificity
GDF-8, GDF8, MSTN, Myostatin, Growth/differentiation factor 8
Purification
Protein A or G purified from cell culture supernatant.
Purity
>95 % by SDS-PAGE.
Isotype
IgG4 kappa
Alternatives
(show)
Application Details
(hide)
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Concentration
0.57 mg/mL
Buffer
0.01M PBS, pH 7.4.
Storage
4 °C,-20 °C,-80 °C
Storage Comment
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Expiry Date
12 months
Target Details for MSTN (Trevogrumab Biosimilar)
(hide)
Target
MSTN (Trevogrumab Biosimilar)
Alternative Name
Trevogrumab Biosimilar
Target Type
Biosimilar
Background
GDF-8, GDF8, MSTN, Myostatin, Growth/differentiation factor 8
UniProt
O14793
CAS-No
1429201-24-0
Recently viewed
(hide)
You are here:
Homepage
Recombinant anti-MSTN (Trevogrumab Biosimilar) antibody (ABIN7598065)
Chat with us , powered by LiveChat